Skip to main content

The Delhi High Court granted an ex parte interim injunction restraining the defendants from marketing VARDENAFIL and VARDENAFIL HYDROCHLORIDE in India.

The court noted that the defendants product contained the plaintiff Bayer’s patented pharmaceutical preparation, but without its permission to exploit the same. The defendants’ drugs, though not commercially launched in India, were being exported to other countries.

Bayer initiated legal proceedings in India upon learning that drugs infringing its patent, valid till 2018, had been seized by customs authorities in Latvia.

Bayer Intellectual Property GmbH v Vipro Lifescience and anr.

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
•
Sep 25, 2026

India’s startup ecosystem is becoming increasingly innovation-led, and the country’s intellectual property numbers offer an interesting glimpse into

India’s IP Numbers Tell a Bigger Story  About Startup Founders in India
News & Updates, Thought Leadership
•
Sep 21, 2026

First published by Asialaw. By: Lakshmidevi Somanath The law currently provides creators exclusive rights over their creation for a limited time, which

From Innovation Incentives to Technology Diffusion: Protecting IP Created by Agentic AI
News & Updates, Thought Leadership
•
Sep 21, 2026

First published by Lexology. Authors: Lakshmidevi Somanath and Kanishka Vaish I. INTRODUCTION The analysis of intellectual property licensing has usually

IP Licenses in Hybrid form and Royalty Payments Post-Patent Expiration: Balancing Patent Expiration and Continuing Rights to Trade Secrets and Know-How
News & Updates, Thought Leadership
•
Sep 20, 2026

For a startup founder, a cease and desist notice can arrive at an uncomfortable point in the life of a business: when a brand is gaining recognition, a

Is a Cease and Desist Notice Legally Binding in India: Consequences of an IP Dispute for Startups